A nationwide study in Denmark found an association between the use of proton pump inhibitors (PPIs) and increased risk of community-associated Clostridioides difficile infections (CA-CDI), Danish researcher reported today in Clinical Infectious Diseases.
Data indicate amoxicillin-clavulanate is safe and effective and may cut the risk of fluoroquinolone-related harms.
A new report from the Centers for Disease Control and Prevention (CDC) shows some encouraging declines in healthcare-associated infections (HAIs) across four US healthcare settings, including one linked to antibiotic use.
A panel of experts convened by the International Society for Infectious Diseases (ISID) has released a set of recommendations for preventing Clostridioides difficile infections in hospitals in low- and middle-income countries (LMICs).
The University of Texas Health Science Center at Houston (UTHealth) announced yesterday that it has received an $11 million grant from the National Institute of Allergy and Infectious Diseases to conduct a 5-year study to better understand why some critically ill patients develop multidrug-resistant infections.
World Health Organization (WHO) flu vaccine advisors recently met to recommend the strains to include in vaccines for the Southern Hemisphere's 2021 season, which—when compared with the Northern Hemisphere upcoming-season version—swaps out the 2009 H1N1 strain.
A phase 3 trial for a bivalent Clostridioides difficile toxoid vaccine was terminated because of futility, an international team of investigators led by scientists from Sanofi Pasteur reported yesterday in The Lancet Infectious Diseases.
Living with a family member with C difficile increased the risk of contracting the disease 12-fold.
A study by researchers from Detroit Medical Center and Wayne State University highlights the risk of Clostridiodes difficile infection (CDI) among COVID-19 patients linked to antibiotic use. The findings appeared in Emerging Infectious Diseases.
CARB-X today announced an award of up to $1.26 million to Facile Therapeutics of Belmont, California, to develop a new oral drug for recurrent Clostridioides difficile infections.
